Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
NCT ID NCT07757191
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT before surgery, TS-1 after) can improve outcomes for people with resectable gastric or gastroesophageal junction cancer. The study aims to see if this combination increases the chance of a complete response to treatment before surgery and helps patients complete their post-surgery therapy. It is designed specifically for East Asian patients, focusing on balancing effectiveness with tolerability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab combined with chemotherapy (FLOT and TS-1)
- What this could lead to
- If successful, this approach could improve the chance of eliminating gastric cancer before surgery and reduce the risk of recurrence afterward, potentially leading to a new standard of care for East Asian patients.
- What could go wrong
- This is a small, early-phase study, so results may not be definitive. The combination may cause more side effects, and the benefit over standard treatment is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Veterans General Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can a smart drug home in on Hard-to-Treat cancers?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can a Triple-Drug cocktail slow advanced stomach cancer?